secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001104659-26-021869
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics' ralinepag phase 3 meets primary endpoint; 55% risk reduction in PAH clinical worsening
--------------------------------------------------------------------------------

- Ralinepag reduced risk of clinical worsening by 55% vs placebo (HR 0.45, p<0.0001) in phase 3 ADVANCE OUTCOMES study.
- Statistically significant improvements in 6MWD, NT-proBNP, and 47% increased odds of clinical improvement at Week 28.
- 80% of patients on dual background therapy; safety consistent with prostacyclin class; no new signals.
- Company plans to submit NDA to FDA by second half of 2026.
- Full results to be presented at upcoming international conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465926021869/0001104659-26-021869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465926021869/tm267696d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-021869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer